Hormonal, fertility & sexual health
PT-141 (Bremelanotide)
A melanocortin receptor agonist approved in the US for low sexual desire in premenopausal women (Vyleesi).
How it works
It activates the MC4 melanocortin receptor in the brain, increasing sexual desire and arousal from the brain, not through blood flow like Viagra.
What it is used for
Approved for low sexual desire in premenopausal women. Studied for erectile dysfunction.
What the evidence says
The RECONNECT trials showed a modest improvement in desire.
Side effects and cautions
Nausea is common, plus flushing, headache and a temporary rise in blood pressure. Repeated use can darken skin or gums. The label allows one dose per 24 hours and no more than eight per month.
Half-life
About 2.7 hours (label)
Makes sense for
- Premenopausal women with low sexual desire
Does not make sense for
- Uncontrolled high blood pressure or heart disease